Headshot of Lewis Cantley

Lewis Cantley, Ph.D.

Professor of Cell Biology (HMS)
Dana-Farber Cancer Institute
TBA--

Lew Cantley is widely known for his many seminal discoveries in signaling and metabolism, including the identification of PI3 kinase and its role in transformation, as well as groundbreaking work unraveling the complexities of protein kinase signaling--his work has had major impact across virtually every aspect of cancer cell biology. For those of you who are new to the department, Lew was a Cell Bio faculty member from 1992-2003 before transitioning to the then newly formed HMS Department of Systems Biology in 2003. In 2012, Lew was recruited to Weill Cornell in New York City, where he served as Director of the Meyer Cancer Center. There, he built a remarkable program focused on the intersection of metabolism and signaling in cancer.

Lew rejoined the Department of Cell Biology at HMS and the DFCI-Cancer Cell Biology in 2022.  

Dana Farber Cancer Institute

Cancer Cell Biology

Faculty Assistant

A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
Authors: Authors: Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, Roberts TM.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
Authors: Authors: Jiang JK, Boxer MB, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ.
Bioorg Med Chem Lett
View full abstract on Pubmed
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply.
Authors: Authors: Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon SO, Cantley LC, Blenis J.
Mol Cell
View full abstract on Pubmed
Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin.
Authors: Authors: Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, May PS, Choi S, Logan TP, Turk BE, Cantley LC, Manolopoulou M, Tang WJ, Stein RL, Cuny GD, Selkoe DJ.
PLoS One
View full abstract on Pubmed
Identification of small molecule inhibitors of pyruvate kinase M2.
Authors: Authors: Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC.
Biochem Pharmacol
View full abstract on Pubmed
Characterization of PXK as a protein involved in epidermal growth factor receptor trafficking.
Authors: Authors: Takeuchi H, Takeuchi T, Gao J, Cantley LC, Hirata M.
Mol Cell Biol
View full abstract on Pubmed
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
Authors: Authors: Boxer MB, Jiang JK, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ.
J Med Chem
View full abstract on Pubmed
The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism.
Authors: Authors: Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Targeting the PI3K signaling pathway in cancer.
Authors: Authors: Wong KK, Engelman JA, Cantley LC.
Curr Opin Genet Dev
View full abstract on Pubmed
Introduction.
Authors: Authors: Yuan TL, Cantley LC.
Curr Top Microbiol Immunol
View full abstract on Pubmed